Franklin Resources Inc. Sells 23,510 Shares of PROCEPT BioRobotics Corporation $PRCT

Franklin Resources Inc. cut its position in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 6.2% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 354,762 shares of the company’s stock after selling 23,510 shares during the period. Franklin Resources Inc. owned approximately 0.64% of PROCEPT BioRobotics worth $20,434,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in PRCT. CWM LLC raised its holdings in PROCEPT BioRobotics by 69.5% in the 1st quarter. CWM LLC now owns 873 shares of the company’s stock worth $51,000 after acquiring an additional 358 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of PROCEPT BioRobotics in the 1st quarter worth $208,000. TD Asset Management Inc increased its holdings in shares of PROCEPT BioRobotics by 13.5% in the 1st quarter. TD Asset Management Inc now owns 118,244 shares of the company’s stock worth $6,889,000 after purchasing an additional 14,044 shares in the last quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych purchased a new position in shares of PROCEPT BioRobotics in the first quarter worth $932,000. Finally, Blair William & Co. IL lifted its holdings in shares of PROCEPT BioRobotics by 12.5% during the first quarter. Blair William & Co. IL now owns 470,286 shares of the company’s stock valued at $27,399,000 after purchasing an additional 52,392 shares in the last quarter. Hedge funds and other institutional investors own 89.46% of the company’s stock.

PROCEPT BioRobotics Stock Down 1.8%

Shares of PRCT stock opened at $31.68 on Friday. The company has a current ratio of 8.44, a quick ratio of 7.20 and a debt-to-equity ratio of 0.14. PROCEPT BioRobotics Corporation has a 12 month low of $27.80 and a 12 month high of $100.89. The stock has a market cap of $1.77 billion, a P/E ratio of -20.71 and a beta of 0.98. The company has a 50 day simple moving average of $33.64 and a two-hundred day simple moving average of $45.35.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.03. The business had revenue of $83.33 million for the quarter, compared to analysts’ expectations of $80.78 million. PROCEPT BioRobotics had a negative net margin of 28.20% and a negative return on equity of 21.72%. The company’s revenue was up 42.6% compared to the same quarter last year. During the same quarter last year, the company posted ($0.40) EPS. PROCEPT BioRobotics has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS. On average, research analysts expect that PROCEPT BioRobotics Corporation will post -1.75 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on PRCT shares. Wells Fargo & Company decreased their target price on PROCEPT BioRobotics from $58.00 to $51.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. Truist Financial reduced their price target on shares of PROCEPT BioRobotics from $64.00 to $50.00 and set a “buy” rating for the company in a research note on Wednesday, October 15th. Leerink Partners reissued an “outperform” rating and set a $55.00 price objective on shares of PROCEPT BioRobotics in a report on Wednesday, November 5th. Oppenheimer upgraded shares of PROCEPT BioRobotics from a “market perform” rating to an “outperform” rating and set a $60.00 target price on the stock in a report on Tuesday, September 2nd. Finally, BTIG Research reaffirmed a “neutral” rating on shares of PROCEPT BioRobotics in a research report on Tuesday, September 16th. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $59.78.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).